TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02507596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nano-crystalline hydroxyapatite silica gel
Description: it is a type of synthetic bone graft.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: open flap debridement
Description: a periodontal surgical procedure for the purpose of debridement.
Study: NCT00506402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: Capsule, 30 mg and 100 mg, BID, continuous dosing
Study: NCT04983693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia-friendly Worship Service
Description: Key elements of dementia-friendly worship services include familiar hymns, prayers and bible stories and short sermons. Participants can attend the worship services either in person or through online video streaming. Participant dyads should watch the six worship services together, over a span of 6 to 8 weeks.
Study: NCT03417583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol Intervention Group
Description: For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
Study: NCT03843151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral solution
Study: NCT04755998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of virtual reality glasses during vaccination applications in children
Description: To the experimental group:~Before the vaccine administration;~* Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.~* Cartoons and virtual reality glasses that the student wanted to watch were prepared.~* While the nurse was preparing the vaccines, the student was put on virtual reality glasses and the distance settings of the lenses were adjusted and the cartoons he chose to watch during the vaccination applications started to be shown. Since virtual reality glasses can cause anxiety attacks manifested by nausea in some children, this was also tested beforehand. It took about two minutes to administer the vaccine and watch cartoons.~Those applied after the vaccine administration;~- Children's Fear Scale, and Children's Anxiety Scale-State Scale was applied to the student.
Study: NCT03462758

Intervention type: DEVICE
Group type: OTHER
Intervention: IUD
Description: Postpartum IUD placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD
Description: Postpartum IUD placement
Study: NCT00540592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
Description: Single dose, Intramuscular injection, 8 different formulations were tested (one per group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
Description: Single dose, Intramuscular injection, 8 different formulations were tested (one per group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
Description: Single dose, Intramuscular injection, 8 different formulations were tested (one per group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
Description: Single dose, Intramuscular injection, 8 different formulations were tested (one per group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
Description: Single dose, Intramuscular injection, 8 different formulations were tested (one per group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
Description: Single dose, Intramuscular injection, 8 different formulations were tested (one per group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
Description: Single dose, Intramuscular injection, 8 different formulations were tested (one per group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GlaxoSmithKline Biologicals' influenza vaccine GSK576389A
Description: Single dose, Intramuscular injection, 8 different formulations were tested (one per group)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: Single dose, Intramuscular injection
Study: NCT01927263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NI-071
Description: 100mg/vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 100mg/vial
Study: NCT04284501

Intervention type: BEHAVIORAL
Intervention: Non
Description: questionnaire

Intervention type: BEHAVIORAL
Intervention: Non
Description: questionnaire
Study: NCT03391986

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEIRIN® Pyonex™ Acupuncture Needles
Description: Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: 12 mm Plasters
Description: 12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
Study: NCT02385942

Intervention type: DEVICE
Group type: OTHER
Intervention: Smart phone
Description: * measure the Live assessed wound size and the transmitted Smart phone-based wound size~* determine dressing materials using Smart phone-based tele-consultation
Study: NCT02516397

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omnia
Description: 12weeks of treatment
Study: NCT02045251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pylera based reduced regimen
Description: Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
Study: NCT01494987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine tablet(s) administered orally
Study: NCT02516397

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12weeks of treatment
Study: NCT03931499

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomic analysis
Description: Blood will be collected in all patients blood before surgery and after surgery (postoperative day 1). Our study is based on a polar metabolomics profiling of plasma and/or serum using hybrid triple quadrupole mass spectrometer coupled with chromatographic system.
Study: NCT03399279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridment
Description: Full mucoperiosteal flap reflected+ Debridement of infrabony defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridment
Description: Full mucoperiosteal flap reflected+ Debridement of infrabony defect
Study: NCT01494987

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ranolazine for the duration of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
Study: NCT03399279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perforated collagen membrane
Description: Membrane perforations using dental needle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive membrane
Description: Biotech collagen membrane

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nanohydroxyapetite
Description: Nanbone Particles
Study: NCT01494987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
Study: NCT03399279

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nanohydroxyapetite
Description: Nanbone Particles
Study: NCT00382265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin
Description: tamsulosin 0.4mg po qd for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo po qd for 28 days
Study: NCT01458301

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
Study: NCT01494987

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.
Study: NCT01458301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385
Description: TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Leuprorelin acetate
Description: TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
Study: NCT01494987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.
Study: NCT02069873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16-Week Group Treatment
Description: Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
Study: NCT00700622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: Technosphere Insulin Inhalation Powder 15U or 30U

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Lantus-injectible supplied as 3mL (300 units) pens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Humalog autopen cartridges pre-filled with 3mL (300 units)
Study: NCT02021786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone based intervention
Description: Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
Study: NCT01396356

Intervention type: PROCEDURE
Intervention: GI procedures
Description: If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
Study: NCT03110211

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapist Evaluation
Description: Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Care Physician
Description: Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
Study: NCT00400517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: doses up to 400 mg/day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: SOC care surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: post radical prostatectomy
Study: NCT01154335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
Study: NCT01494987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.
Study: NCT01154335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
Study: NCT03096392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDV insulin lispro 100 UNT/ML
Description: HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
Study: NCT02833519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group exercise
Description: 1. Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~   The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~   The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~2. The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~3. A weekly supportive email.
Study: NCT03713606

Intervention type: PROCEDURE
Intervention: HVPG measurement
Description: HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
Study: NCT01072968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF2.649
Description: 1 capsule per day in the morning before the breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day in the morning before the breakfast
Study: NCT02679794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Egg consumption
Description: Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
Study: NCT03096392

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro 100 UNT/ML
Description: Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
Study: NCT01973231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lixisenatide
Description: Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
Study: NCT02084498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated bolus calculator
Description: Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
Study: NCT01344785

Intervention type: PROCEDURE
Intervention: Intramedullary nailing
Description: All patients will be treated with Intramedullary nailing
Study: NCT00917397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: varies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: varies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: trauma-focused cognitive behavioural therapy
Description: once a week
Study: NCT00878891

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring for immediate correction of abnormal glycemia
Description: Prevention of hyper and hypo glycemia
Study: NCT02084498

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Carbohydrate Counting
Description: Training in advanced carbohydrate counting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Carbohydrate Counting
Description: Training in advanced carbohydrate counting.
Study: NCT00878891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring for immediate correction of abnormal glycemia
Description: Prevention of hyper and hypo glycemia
Study: NCT04445350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Focus Of Attention
Description: Instructions and feedback are used to direct the learner's focus to an external source (e.g. the effect the intended movement has) promoting long-term learning by stimulating automatic cognitive control processes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internal Focus Of Attention
Description: In contrast, adopting an internal focus of attention (e.g. focus on specific body areal) can disrupt automatic control processes and interfere automatic movement.
Study: NCT02995512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg tablets
Description: 1.2 mg PO followed by 0.6 mg PO 1 hour later
Study: NCT03276832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Applied cutaneously

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03576781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real iTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real cTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cTBS
Description: This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
Study: NCT03005236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENVARSUS
Description: Envarsus is a once-a-day oral formulation of tacrolimus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard twice daily tacrolimus
Description: Standard tacrolimus will include twice-daily formulations that are currently available.
Study: NCT02052869

Intervention type: PROCEDURE
Group type: OTHER
Intervention: esophagus intubation
Description: In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
Study: NCT00534768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active debridement
Description: debridement on 1st, 3-5th and 7th postoperative days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Postoperative debridement on 7th postoperative day